“For women who start with BMD levels above [–2.8 in the total hip or –3.1 in the lumbar spine], denosumab is appropriate,” Cosman told Healio. “However, for women who start with T-scores ...
Researchers predicted the likelihood of achieving target T-scores in postmenopausal women with osteoporosis who received denosumab therapy for 10 years.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results